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Abstract
Background: Glycopeptides such as vancomycin are frequently the antibiotics of choice for the
treatment of infections caused by methicillin resistant Staphylococcus aureus (MRSA). For the last 7
years incidence of vancomycin intermediate S. aureus and vancomycin resistant S. aureus (VISA and
VRSA respectively) has been increasing in various parts of the world. The present study was carried
out to find out the presence of VISA and VRSA in the northern part of India.
Methods: A total 1681 staphylococcal isolates consisting of 783 S. aureus and 898 coagulase
negative staphylococci (CoNS) were isolated from different clinical specimens from various
outpatient departments and wards. All S. aureus and 93 CoNS were subjected to MIC testing
(against vancomycin, teicolplanin and oxacillin); Brain Heart Infusion (BHI) vancomycin screen agar
test; disc diffusion testing, and PCR for mecA, vanA and vanB genes detection.
Results: Out of 783 S. aureus two S. aureus strains were found to be vancomycin and teicoplanin
resistant (one strain with MIC 32 µg/ml and the other strain with MIC 64 µg/ml); six strains of S.
aureus have shown to be vancomycin intermediate (two strains with MIC 16 µg/ml and four strains
with MIC 8 µg/ml); and two strains with teicoplanin intermediate (MIC 16 µg/ml). One CoNS strain
was resistant to vancomycin and teicoplanin (MIC 32 µg/ml), and two CoNS strains were
intermediate to vancomycin and teicoplanin (MIC 16 µg/ml). All VRSA, VISA and vancomycin
resistant CoNS had shown growth on BHI vancomycin screen agar (vancomycin 6 µg/ml) and were
mecA PCR positive. None of these isolates have demonstrated vanA/vanB gene by PCR.
Conclusion: The present study reveals for the first time emergence of VISA/VRSA from this part
of world and indicates the magnitude of antibiotic resistance in and around the study area. The
major cause of this may be unawareness and indiscriminate use of broad-spectrum antibiotics.
Background
Staphylococcus aureus has long been recognized as a major
pathogen of hospital acquired infections. Over the last
decade, methicillin resistant S. aureus (MRSA) strains have
become endemic in hospitals worldwide. In addition, it is
now incipient community pathogen in many geographi-
cal regions [1]. MRSA is important because, in addition to
being methicillin resistant, most strains are also resistant
to other β-lactam antibiotic, with the exception of glyco-
peptide antibiotics [2,3]. In 1980s, because of widespread
occurrence of MRSA, empiric therapy for staphylococcal
infections (particularly nosocomial sepsis) was changed
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to vancomycin in many health care institutions. Vanco-
mycin use in United States also increased during this
period because of the growing numbers of infections with
Clostridium difficile and coagulase negative staphylococci
(CoNS) in health care institutions [4,5]. Thus, the early
1990s have shown a discernible increase in vancomycin
use. As a consequence, selective pressure was established
that eventually lead to the emergence of strains of S.
aureus and other species of staphylococci with decreased
susceptibility to vancomycin and other glycopeptides [6].
In 1997, the first strain of S. aureus with reduced suscepti-
bility to vancomycin and teicoplanin was reported from
Japan [7]. Shortly after, two additional cases were
reported from United States [8]. However, first clinical
isolate of vancomycin resistant S. aureus (VRSA) was
reported from United States in 2002 [9]. More recently
some workers have reported vancomycin resistant staphy-
lococcal stains from Brazil [10] and Jordan [11].
Strains of Vancomycin Intermediate S. aureus (VISA) with
vancomycin MIC of 8 µg/ml have been reported from
Japan [7], United States [12-14], France [15], United King-
dom [16] and Germany [17]. Most of these isolates appear
to have developed from preexisting MRSA infections.
Assadullah et al from India have reported reduced suscep-
tibility of vancomycin against MRSA and CoNS [18].
Keeping this in view we performed extensive longitudinal
study of total 1681 staphylococcal strains for the assess-
ment of current situation of vancomycin resistance in
northern part of India. This is the first report of VRSA
emergence from a tertiary care hospital from this part of
world.
Methods
Staphylococcal Isolates
A total 1681 staphylococcal isolates consisting of 783 S.
aureus and 898 CoNS were investigated for the period of
three years from August 2002 to July 2005. The strains
were collected from various clinical specimens including
pus, urine, wound swabs, catheters, blood, sputum and
CSF from the patients of different inpatient and outpa-
tient departments of the University Hospital, BHU. This is
a tertiary care teaching hospital, which serves the popula-
tion of eastern region of Uttar Pradesh and adjoining dis-
tricts of Bihar, Jharkhand and Madhya Pradesh, India.
Media and Culture Conditions
All clinical samples except urine were first inoculated onto
blood agar (Hi-Media, India) and MacConkey agar (Hi-
Media, India) plates whereas the urine samples were inoc-
ulated only on CLED agar (Hi-Media, India) plates. The
plates were incubated at 37°C for 24–48 h. The identifica-
tion of isolates was done according to standard method
described elsewhere [19].
Growth on Mannitol Salt Agar
All staphylococcal isolates were again inoculated onto
mannitol salt agar (Hi-Media, India) and plates were incu-
bated at 37°C for 24–48 h. Mannitol fermentation was
observed and recorded.
Coagulase Test
Slide coagulase tests of all 1681 isolates were performed
by emulsifying few pure colonies of staphylococci from
blood agar on undiluted rabbit plasma. Tube coagulase
tests were performed by diluting the plasma in freshly pre-
pared normal saline (1:6). Three to four pure colonies
were emulsified in 1 ml of diluted plasma and the tubes
were incubated at 37°C. Readings were taken at 1 h, 2 h,
3 h, and 4 h and further incubated overnight at room tem-
perature if no clot formation was observed. S. aureus
ATCC 29213 was used as control strain [19].
Latex agglutination test (Slidex Staph Plus)
Latex agglutination test on all clinical isolates was per-
formed according to the protocols supplied by the manu-
facturer (Biomerurix India Ltd, New Delhi, India).
Determination of Minimum Inhibitory Concentration 
(MIC)
MIC of oxacillin (Hi-Media, India), vancomycin (Lilly
Pharma, Giessen, Germany) and teicoplanin (Gruppo
Lepetit, Angani, Italy) were determined by agar dilution
method as described elsewhere [20]. Briefly, gradient
plates of Mueller-Hinton agar (Hi-Media, India) were pre-
pared with oxacillin (0.25–256 µg/ml) (with 2% NaCl),
vancomycin (0.5–128 µg/ml) and teicoplanin (0.5–128
µg/ml). By direct colony suspension method 0.5 McFar-
land equivalent inouculum were prepared in normal
saline from 18–24 h agar plate culture. The suspension
was further diluted to achieve desired inoculum concen-
tration of 105 CFU/ml. All strains were spotted onto gradi-
ent plates. Plates were incubated overnight at 35°C for
any visible growth. Readings were taken according to
NCCLS guidelines [20]. S. aureus ATCC 29213 and Entero-
coccus faecalis ATCC 29212 strains were used as vancomy-
cin susceptible controls and E. faecalis ATCC 51299 as
vancomycin resistant control.
Inoculation on BHI vancomycin screen agar
In-house prepared BHI agar (Hi-Media, India) screen
plates containing 6 µg/ml vancomycin (Lilly Pharma,
Giessen, Germany) were prepared. Inoculum suspensions
were prepared by selecting colonies from overnight
growth on nutrient agar plates. The colonies were trans-
ferred to sterile saline to produce a suspension that
matches the turbidity of a 0.5 McFarland standard. The
final inoculum concentration of 105 to 106 CFU per spot
was prepared by adding the sterile saline to the bacterial
suspension. These suspensions were inoculated onto BHIBMC Infectious Diseases 2006, 6:156 http://www.biomedcentral.com/1471-2334/6/156
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screen agar plates and were incubated for 24 h at 35°C in
ambient air. Any visible growth indicated the vancomycin
resistance. S. aureus ATCC 29213 and Enterococcus faecalis
ATCC 29212 strains were used as a vancomycin suscepti-
ble control strains and E. faecalis ATCC 51299 as vanco-
mycin resistant control strain.
Disc Diffusion
Disc diffusion test of Penicillin (10 U), Oxacillin (1 µg),
Gentamicin (10 µg), Tobramycin (30 µg), Amikacin (30
µg), Netilmicin (30 µg), Norfloxacin (10 µg), Cipro-
floxacin (5 µg), Chloramphenicol (30 µg), Erythromycin
(15 µg), Tetracycline (15 µg), Trimethoprim/Sulfameth-
axole (1.25/23.75 µg), Nitrofurantoin (300 µg), Vanco-
mycin (30 µg), Cefoperazoneoxacillin/Sulbactam (75/30
µg) was carried out using Kirby-Bauer Method as
described elsewhere [20]. Mueller-Hinton agar plates were
overlaid with the inoculum (turbidity equivalent to that
of a 0.5 McFarland Standard) of the S. aureus clinical
strains. Zone diameters were measured at 24 and 48 h fol-
lowing NCCLS criteria [20]. S. aureus ATCC 29213 was
used as reference strain.
Detection of mecA gene by PCR
Staphylococcal DNA was isolated using classical chloro-
form: phenol extraction method described elsewhere [21].
The oligonucleotide primers for mecA gene (mecA F 5'
GTAGAAATGACTGAACGTCCGATGA 3' and mecA  R 5'
CCAATTCCACATTGTTTCGGTCTAA 3') and reaction con-
dition previously reported were used [22]. A Biometra
DNA thermocycler was programmed with the initial dena-
turation, 4 min at 94°C; 30 cycles with a 45-s denatura-
tion step at 94°C, a 45-s annealing step at 56°C and a 30-
s extension step at 72°C and 2 min extension step at 72°C
and a holding step at 4°C until the sample was analyzed.
The PCR products were electrophoresed, stained with 10
µM ethidium bromide and visualized by using UV transil-
lumination. The positive tests have shown PCR product of
310 bp. S. aureus ATCC 29213, reference strain was used
mecA positive control strain, and S. aureus ATCC 43300 as
mecA negative control strain.
Detection of vanA and vanB genes by PCR
Staphylococcal DNA was isolated as described above [21].
Oligonucleotide primers for vanA (vanA F 5'CATGAATA-
GAATAAAAGTTGCAATA 3'and vanA  R 5'CCCCTT-
TAACGCTAATACGACGATCAA 3') and vanB (vanB F 5'
GTGACAAACCGGAGGCGAGGA 3' and vanB
R5'CCGCCATCCTCCTGCAAAAAA 3') genes and reaction
condition previously reported were used [23]. A Biometra
DNA thermocycler was programmed with the initial dena-
turation, 10 min at 94°C; 30 cycles with a 30-s denatura-
tion step at 94°C, a 45-s annealing step at 50°C and a 30-
s extension step at 72°C and 10 min extension step at
72°C and a holding step at 4°C until the sample was ana-
lyzed. The PCR products were electrophoresed, stained
with 10 µM ethidium bromide and visualized by using UV
transillumination. Enterococcus faecalis A256 and Entero-
coccus faecalis V583 were used vanA and vanB positive con-
trol strains respectively whereas Enterococcus faecalis ATCC
29212 was used as vanA/B negative control strain.
Results
Out of 1681 staphylococcal isolates, 761 isolates were
slide coagulase positive, 772 were slidex staph plus posi-
tive, and 783 were tube coagulase positive. Thus, 783
strains were confirmed as S. aureus and remaining 898
strains as CoNS.
MIC of 783 S. aureus strains and 93 CoNS against oxacillin
had shown that 318 S. aureus stains and 51 CoNS strains
were resistant to oxacillin (MIC ≥ 4 µg/ml for S. aureus and
MIC ≥ 0.5 µg/ml for CoNS). Out of 318 oxacillin resistant
S. aureus strains, total two strains were found to be VRSA
strains. One strain had shown vancomycin and teico-
planin MIC 32 µg/ml and the other strain with vancomy-
cin and teicoplanin MIC 64 µg/ml. Out of 51 oxacillin
resistant CoNS, one strain had shown vancomycin and
teicoplanin MIC 32 µg/ml. Six strains of S. aureus were to
be found vancomycin intermediate S. aureus (two strains
with MIC of 16 µg/ml and four strains with MIC of 8 µg/
ml). Two S. aureus strains were to be teicoplanin interme-
diate (MIC 16 µg/ml). The detailed description of all van-
comycin intermediate/resistant S. aureus strains are given
in table 1.
All oxacillin resistant S. aureus and CoNS strains had
shown presence of mecA gene be PCR methods. All VISA,
VRSA and vancomycin intermediate and resisistant CoNS
strains were grown on BHI vancomycin screen agar. Disc
diffusion test revealed that all vancomycin resistant sta-
phylococcal isolates have shown antimicrobial resistance
to most of the commonly used antimicrobials (table 2).
However, none of theses strains could demonstrate the
presence of vanA and or vanB gene by PCR.
Discussion
In the routine microbiology laboratory prompt identifica-
tion of the staphylococcal strains up to species level were
done by catalase, coagulase and other standard biochem-
ical test. However during routine screening by slide coag-
ulase test many strains of S. aureus are missed due to their
poor sensitivity and falsely reported as coagulase negative
staphylococci during routine screening process. In our
study we performed tube coagulase tests of all 1681 sta-
phylococcal strains. Therefore the main criterion used for
the S. aureus identification was tube coagulase test. How-
ever, the slidex staph plus test was also found to be good
to differentiate S. aureus and CoNS.BMC Infectious Diseases 2006, 6:156 http://www.biomedcentral.com/1471-2334/6/156
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MICs of oxacillin, vancomycin and teicoplanin against S.
aureus and CoNS revealed that there is a rise in the resist-
ance. S. aureus and CoNS have shown 40.61 % and 54.83
% oxacillin resistance, respectively. We have found two
MRSA strains which were showing vancomycin resistance
(VRSA). These VRSA strains have been isolated from the
pus of two different patients who were admitted in the dif-
ferent wards. One VRSA (vancomycin MIC 64 µg/ml)
strain was isolated from pus of a 56 years old patient who
was admitted in Medicine ward and; the other VRSA (van-
comycin MIC 32 µg/ml) strain was isolated from pus of a
49 years old patient who was admitted in Skin and VD
ward of our hospital (table 1). Both the isolates were also
found to be resisistant to several other antimicrobials such
as gentamicin, tobramycin, amikacin, norfloxacin, cipro-
floxacin, erythromycin, tetracycline, trimethoprim/sul-
famethoxazole and cefoperazone/sulbactam (table 2).
While going through the detailed history of these two
patients it was found that they were already treated with
glycopeptides for more than 20 days. These patients were
not responding to further vancomycin therapy and later
died due to complication of the disease.
The present study also encountered one vancomycin
resistant CoNS strain with vancomycin and teicoplanin
MIC 32 µg/ml. The strain was later identified as Staphylo-
coccus epidermidis. This strain was isolated from culture of
tip of endo-trachial tube of a patient who was admitted in
the intensive care unit of teaching hospital.
Of total six VISA strains, four had their MIC 8 µg/ml and
two strains showed vancomycin and teicoplanin MIC of
16 µg/ml. Out of six VISA strains, two were isolated from
the pus specimens of the patient visiting outpatient
department and remaining four were from the pus speci-
mens of patients admitted in post-operative ward.
Out of two strains of CoNS (Staphylococcus epidermidis)
with vancomycin and teicoplanin MIC 16 µg/ml, one was
isolated from the blood of a patient who was admitted in
orthopedic ward, and the other was isolated from the
urine specimen of a patient visiting the endocrinology
outpatient department.
In this study we have found almost similar pattern of MIC
of vancomycin and teicoplanin. The present study shows
that there is a significant rise of reduced susceptibility of
Table 2: Resistance pattern of vancomycin resistant staphylococcal isolates to commonly tested antimicrobial agents as determined by 
disc diffusion method.
Strains Resistant/Intermediate Sensitive
S. aureus (MIC van 64 µg/ml) Pen, Oxa, Gen, Tob, Amik, Net, Nor Cip, Chl, Ery, Tri/Sul, Cefo/Sul, Van Tet, Nit
S. aureus (MIC van 32 µg/ml) Pen, Oxa, Gen, Tob, Amik, Net, Nor, Cip, Chl, Ery, Tri/Sul, Nit, Van Tet, Cefo/Sul
S. aureus(MIC van 16 µg/ml) Pen, Oxa, Gen, Tob, Amik, Net, Nit, Nor, Cip, Ery, Van Chl, Tri/Sul, Cefo/Sul
S. aureus(MIC van 8 µg/ml) Pen, Oxa, Gen, Tob, Amik, Net, Nor, Cip, Ery, Van Tri/Sul, Nit, Cefo/Sul
S. epidermidis (MIC van 32 µg/ml) Pen, Oxa, Gen, Tob, Amik, Net, Nor, Cip, Chl, Ery, Cefo/Sul, Nit, Van Tri/Sul
S. epidermidis (MIC van 16 µg/ml) Pen, Oxa, Gen, Tob, Net, Nor, Cip, Ery, Van Tri/Sul, Nit, Amik, Cefo/Sul
Pen: Penicillin, Oxa: Oxacillin, Gen: Gentamicin, Tob: Tobramycin, Amik: Amikacin, Net: Netilmicin, Nor: Norfloxacin, Cip: Ciprofloxacin, Chl: 
Chloramphenicol, Ery: Erythromycin, Tet: Tetracycline, Nit: Nitrofurantoin Tri/Sul: Trimethoprim/Sulfamethaxole, Cefo/Sul: Cefoperazoneoxacillin/
Sulbactam, Van: Vancomycin.
Table 1: Detailed description of vancomycin resistant staphylococcal strains.
Strains No. of Isolates MIC vancomycin 
(µg/ml)
MIC teicoplanin 
(µg/ml)
Specimens Prior 
vancomycin use 
history
Ward/OPD
S. aureus* (VRSA) 1 64 64 Pus Yes Surgery ward
S. aureus* (VRSA) 1 32 32 Pus Yes Skin ward
S. aureus** (VISA) 2 16 16 Pus No Orthopedic OPD
S. aureus** (VISA) 4 8 8 Pus No Post-operative ward
S. epidermidis 
(VRSE)
1 32 32 Tip of ETT Yes Intensive care unit
S. epidermidis 
(VISE)
1
1
16
16
16
16
Blood
Urine
No
No
Endocrinology OPD
Post-operative ward
*According to NCCLS guidelines (2000) these strains have been designated as Vancomycin Resistant Staphylococcus aureus.
**According to NCCLS guidelines (2000) these strains have been designated as Vancomycin Intermediate Staphylococcus aureus.BMC Infectious Diseases 2006, 6:156 http://www.biomedcentral.com/1471-2334/6/156
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oxacillin, vancomycin and teicoplanin. The emergence of
the glycopeptide resistance is of great concern. Though
first case of VRSA was reported in 2002 in USA [9] but few
other countries have reported the reduced susceptibility of
S. aureus and CoNS against glycopeptides [6-8,10,11,13-
18]. Recently Pallazo et al [10] have also reported some
vancomycin resistant strains of CoNS in Brazil. More
recently Bathaineh has reported VRSA strains from Jordan
[11]. Ashdulla et al [18] have reported some strains of
vancomycin intermediate S. aureus (VISA) from India.
Song et al, 2004 have also been reported the emergence of
heterogeneous vancomycin resistant S. aureus strains from
India and its neighboring countries [24]. The current van-
comycin resistant staphylococci in hospital as well as in
community are alarming situation to the clinicians. The
development of antibiotic resistance in developing coun-
tries like ours seems to be very much related to the irra-
tional antibiotic usage due to it's easy availability at the
drug store without prescription, injudicious use in hospi-
tals and uncontrolled use in agriculture, animal hus-
bandry and fisheries [25]. This emergence of VRSA/VISA
may be due to building of selective pressure of vancomy-
cin. Vancomycin, a glycopeptide is currently the main
antimicrobial agent available to treat life-threatening
infections with MRSA. Until recently vancomycin resist-
ance among gram-positive bacteria had been thought to
be uncommon but the confirmed reports of vancomycin
resistance in Enterococcus spp; S. aureus and CoNS have
been reported from various part of world. Widespread use
of vancomycin to treat infections caused by MRSA and
other gram-positive cocci has led to the emergence of van-
comycin resistance. The large scale of development and
subsequent spread of resistance to vancomycin has been
perceived as a fearsome threat to the already challenging
therapy of MRSA.
The true mechanism of vancomycin resistance in S. aureus
is not known. It was initially feared that S. aureus would
acquire the van gene that code for vancomycin resistance
in  Enterococcus spp; this phenomenon was successfully
accomplished in the laboratory [26]. Further, Showsh et
al, 2001 [27] have demonstrated the presence of sex phe-
romone in S. aureus that promotes plasmid transfer in
Enterococcus spp. Release of these pheromones by S. aureus
with proximity to vancomycin-resistant enterococci
causes the transfer of plasmids encoding van gene to the S.
aureus.
In current study all strains of VRSA and VISA strains were
negative for vanA/vanB  gene by PCR. Therefore the
absence of vanA/B genes in the present isolates dose not
rule out that these strains are not VRSA or VISA. There is
another hypothesis which says that cell wall thickening is
responsible for the development of vancomycin resist-
ance. The mechanism of vancomycin resistance has been
extensively studied with the first clinical VRSA strain,
Mu50 [28-30]. Biochemical and transmission electron
microscopy (TEM) examination of the Mu50 cell, sug-
gested that it produces increased amounts of peptidogly-
can. More murein monomers and more layers (probably
30–40 layers as judged by cell-wall thickness observed
with TEM) of peptidoglycan are considered to be present
in the cell wall. As a result, more vancomycin molecules
are trapped in the peptidoglycan layers before reaching
the cytoplasmic membrane where peptidoglycan synthe-
sis occurs. Moreover, a higher concentration of vancomy-
cin would be required to saturate all the murein
monomers that are supplied at an increased rate in Mu50.
Besides the vancomycin-trapping mechanism, designated
"affinity trapping," [31-33], Hiramatsu has suggested that
dense accumulation of vancomycin molecules within the
thickened cell-wall significantly delays the timing of com-
plete inhibition of cell-wall synthesis by not allowing effi-
cient penetration of vancomycin molecules through the
thickened cell-wall layers [30].
The thickened cell wall of VRSA strains become thinner
with the loss of vancomycin resistance during the drug
free passage and again become thick in resistant mutants.
Pallazo et al [10] have also demonstrated the thickening
of cell wall in vancomycin resistant staphylococci. This
could be the possible mechanism behind the vancomycin
resistant staphylococcal isolates that we have reported
though we could not perform the test for the demonstra-
tion of cell wall thickening in these isolates.
Conclusion
Our study for the first time has exposed the emergence of
VRSA and VISA in North India. Although we confined our
study within North India, the emergence of VRSA/VISA
might also be prevalent in other parts of India as antibi-
otic misuse is equally common there. Hence, there should
be an immediate response from the concerned authorities
to check further emergence and spreading of these notori-
ous VRSA strains. A strict regulation on irrational antibi-
otic usages might be an appropriate and effective
approach in this direction. Moreover, nationwide surveil-
lance program should be carried out to map the vancomy-
cin susceptibility pattern in this country. For this, all
strains with vancomycin MIC 4 µg/ml should be ear-
marked and sent to the reference laboratory for the further
characterization. This will help to identify the potential
areas which are already under the major threat of VRSA/
VISA emergence and therefore draw more focused atten-
tion of Government for prompt tackling of this problem.
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